Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,526,548
  • Shares Outstanding, K 135,880
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ 98 M
  • EBITDA $ 116 M
  • 60-Month Beta 1.28
  • Price/Sales 11.44
  • Price/Cash Flow 584.84
  • Price/Book 19.18

Options Overview Details

View History
  • Implied Volatility 71.02% (+2.40%)
  • Historical Volatility 91.53%
  • IV Percentile 58%
  • IV Rank 33.71%
  • IV High 118.81% on 04/08/25
  • IV Low 46.72% on 07/07/25
  • Expected Move (DTE 22) 8.16 (11.64%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 671
  • Volume Avg (30-Day) 2,661
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 33,608
  • Open Int (30-Day) 36,564
  • Expected Range 61.95 to 78.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.80
  • Number of Estimates 6
  • High Estimate 1.63
  • Low Estimate -0.02
  • Prior Year -1.39
  • Growth Rate Est. (year over year) +157.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.72 +60.36%
on 11/25/25
72.36 -3.11%
on 12/11/25
+25.85 (+58.40%)
since 11/24/25
3-Month
31.45 +122.89%
on 09/26/25
72.36 -3.11%
on 12/11/25
+37.28 (+113.55%)
since 09/24/25
52-Week
9.57 +632.60%
on 04/07/25
72.36 -3.11%
on 12/11/25
+50.48 (+257.16%)
since 12/24/24

Most Recent Stories

More News
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiMâ„¢) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier - Study initiation...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Annual Healthcare Conference...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

- Conference Call and Webcast Today, November 25, 2025, at 4:30 p.m. ET

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved...

ARWR : 70.11 (+0.40%)
SRPT : 22.32 (+1.45%)
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

- REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS - People living with FCS have extremely high triglyceride...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal...

ARWR : 70.11 (+0.40%)
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions...

ARWR : 70.11 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 74.90
2nd Resistance Point 73.10
1st Resistance Point 71.60
Last Price 70.11
1st Support Level 68.31
2nd Support Level 66.51
3rd Support Level 65.01

See More

52-Week High 72.36
Last Price 70.11
Fibonacci 61.8% 48.37
Fibonacci 50% 40.97
Fibonacci 38.2% 33.56
52-Week Low 9.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar